본문 바로가기
KERD
논문KCI 등재

Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry

김준|김태훈|이영수|박진규|박형욱|정보영|박준범|심재민|김진배|강기운|최의근|박한진|유희태
연세대학교의과대학 (Yonsei University College of Medicine)|2023.01|Yonsei Medical Journal|제64권 제1호|pp. 18-24|DOI 10.3349/ymj.2022.0455

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

strokedialysisbleedingatrial fibrillationAnticoagulant
주제분류의학일반

초록

Purpose: Advanced chronic kidney disease (CKD), including end-stage renal disease (ESRD) on dialysis, increases thromboem bolic risk among patients with atrial fibrillation (AF). This study examined the comparative safety and efficacy of direct-acting oral anticoagulant (DOAC) compared to warfarin or no oral anticoagulant (OAC) in AF patients with advanced CKD or ESRD on dialysis. Materials and Methods: Using data from the COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, 260 non-valvular AF patients with advanced CKD (defined as estimated glomerular filtration rate <30 mL/min per 1.73/m2) or ESRD on dialysis were enrolled from June 2016 to July 2020. The study population was categorized into DOAC, warfarin, and no OAC groups; and differences in major or clinically relevant non-major (CRNM) bleeding, stroke/systemic embolism (SE), myocardial infarction/critical limb ischemia (CLI), and death were assessed. Results: During a median 24 months of follow-up, major or CRNM bleeding risk was significantly reduced in the DOAC group compared to the warfarin group [hazard ratio (HR) 0.11, 95% confidence interval (CI) 0.01 to 0.93, p=0.043]. In addition, the risk of composite adverse clinical outcomes (major or CRNM bleeding, stroke/SE, myocardial infarction/CLI, and death) was significantly reduced in the DOAC group compared to the no OAC group (HR 0.16, 95% CI 0.03 to 0.91, p=0.039). Conclusion: Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcomes compared to no OAC. ClinicalTrials.gov (NCT02786095)

Abstract

Purpose: Advanced chronic kidney disease (CKD), including end-stage renal disease (ESRD) on dialysis, increases thromboem bolic risk among patients with atrial fibrillation (AF). This study examined the comparative safety and efficacy of direct-acting oral anticoagulant (DOAC) compared to warfarin or no oral anticoagulant (OAC) in AF patients with advanced CKD or ESRD on dialysis. Materials and Methods: Using data from the COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, 260 non-valvular AF patients with advanced CKD (defined as estimated glomerular filtration rate <30 mL/min per 1.73/m2) or ESRD on dialysis were enrolled from June 2016 to July 2020. The study population was categorized into DOAC, warfarin, and no OAC groups; and differences in major or clinically relevant non-major (CRNM) bleeding, stroke/systemic embolism (SE), myocardial infarction/critical limb ischemia (CLI), and death were assessed. Results: During a median 24 months of follow-up, major or CRNM bleeding risk was significantly reduced in the DOAC group compared to the warfarin group [hazard ratio (HR) 0.11, 95% confidence interval (CI) 0.01 to 0.93, p=0.043]. In addition, the risk of composite adverse clinical outcomes (major or CRNM bleeding, stroke/SE, myocardial infarction/CLI, and death) was significantly reduced in the DOAC group compared to the no OAC group (HR 0.16, 95% CI 0.03 to 0.91, p=0.039). Conclusion: Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcomes compared to no OAC. ClinicalTrials.gov (NCT02786095)

참고문헌 (29)

  1. Olesen JB, "Stroke and bleeding in atrial fibrillation with chronic kidney disease", N Engl J Med, 367, pp.625~635 (2012)
  2. Laupacis A, "Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials", Arch Intern Med, 154, pp.1449~1457 (1994)
  3. January CT, "2014 AHA", ACC, American Heart Association task force on practice guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
  4. Fauchier L, "Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation", Am Heart J, 198, pp.39~45 (2018)
  5. Ananthapanyasut W, "Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease", Clin J Am Soc Nephrol, 5, pp.173~181 (2010)
  6. Genovesi S, "Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients", Am J Kidney Dis, 46, pp.897~902 (2005)
  7. Sreedhara R, "Defective platelet aggregation in uremia is transiently worsened by hemodialysis", Am J Kidney Dis, 25, pp.555~563 (1995)
  8. Shah M, "Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis", Circulation, 129, pp.1196~1203 (2014)
  9. Winkelmayer WC, "Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation", Clin J Am Soc Nephrol, 6, pp.2662~2668 (2011)
  10. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
  11. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
  12. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
  13. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
  14. 김형수, "A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry", Korean Circulation Journal, 47(6), pp.877~887 (2017), 대한심장학회[DOI]
  15. Hindricks G, "2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)
  16. Chan KE, "Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis", Circulation, 131, pp.972~979 (2015)
  17. Padrini R, "Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure", Eur J Drug Metab Pharmacokinet, 44, pp.1~12 (2019)
  18. Chang M, "Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban", J Clin Pharmacol, 56, pp.637~645 (2016)
  19. Siontis KC, "Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States", Circulation, 138, pp.1519~1529 (2018)
  20. Stanifer JW, "Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease", Circulation, 141, pp.1384~1392 (2020)
  21. Koretsune Y, "Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment", Circ J, 79, pp.1486~1495 (2015)
  22. Wetmore JB, "Direct-acting oral anticoagulants versus warfarin in medicare patients with chronic kidney disease and atrial fibrillation", Stroke, 51, pp.2364~2373 (2020)
  23. Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial", Eur Heart J, 33, pp.2821~2830 (2012)
  24. Bonde AN, "Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease : a nationwide observational cohort study", J Am Coll Cardiol, 64, pp.2471~2482 (2014)
  25. Chan KE, "Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation", J Am Soc Nephrol, 20, pp.2223~2233 (2009)
  26. Gansevoort RT, "Chronic kidney disease and cardiovascular risk : epidemiology, mechanisms, and prevention", Lancet, 382, pp.339~352 (2013)
  27. Sarnak MJ, "Chronic kidney disease and coronary artery disease : JACC state-of-the-art review", J Am Coll Cardiol, 74, pp.1823~1838 (2019)
  28. Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)
  29. Rothberg MB, "Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome : meta-analysis with estimates of risk and benefit", Ann Intern Med, 143, pp.241~250 (2005)

이 간행물의 다른 논문 (9건)

Mathematical Modeling of COVID-19 Transmission and Intervention in South Korea: A Review of Literature최은서, 이지현, 정민영, 안현정, 이효정, 김솔pp. 1-10Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria박용범, 이상원, 표정윤, Lucy Eunju Leepp. 11-17Machine-Learning Model for the Prediction of Hypoxaemia during Endoscopic Retrograde Cholangiopancreatography under Monitored Anaesthesia Care박정엽, 김은화, 심하진, 김광준, 김민수, 이정현, 방승민, 이보라, 조중현, 이희승, 양은호, 박승우, 송시영, 박준형, 정문재, 강화평pp. 25-34High Mean Platelet Volume Is Associated with Cerebral White Matter Hyperintensities in Non-Stroke Individuals김현경, 추승욱, 최정원, 서태호, 이기욱, 오승헌, 노유정, 장예지pp. 35-41Changes in Subjective Outcomes during the Early Period after Septoturbinoplasty이한철, 강주완, 김경수, 박주하, 신근철pp. 42-47
원문 보기